相关实验视频

Updated: May 24, 2025

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

儿科急性淋巴细胞白血病中的急性治疗相关毒性

Shlomit Barzilai Birenboim¹, Ron Rabinowicz²

¹Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, and the Faculty of Medical and Health Sciences, Aviv University. shlombiren@gmail.com.

|March 6, 2025

概括

儿童急性淋巴细胞白血病 (ALL) 的治愈率很高,但治疗毒性存在重大风险. 量身定制的疗法和免疫疗法可以减轻这些急性毒性,改善生存和健康.

科学领域:

儿科瘤学儿科瘤学
血液学血液学血液学
临床毒理学临床毒理学

背景情况:

儿童急性淋巴细胞白血病 (ALL) 的治愈率很高.
与治疗相关的毒性,无论是急性还是慢性,都会显著影响生存率和生活质量.
相当数量的儿童ALL死亡是由于治疗并发症而不是疾病本身造成的.

研究的目的:

审查与儿科ALL治疗相关的主要急性毒性.
探索减轻这些严重治疗相关毒性的策略.
突出量身定制治疗和免疫治疗在改善结果中的作用.

主要方法:

文献综述侧重于ALL治疗的六个关键急性毒性.
对治疗适应和免疫疗法整合的分析.
对整体存活率和患者健康的影响评估.

主要成果:

确定了六种主要的急性毒性:静脉血栓栓塞,骨髓缩,神经后果,延迟的甲状腺素排泄,阿斯巴拉金酶相关的胰腺炎,以及新生物疗法的毒性.
严重的急性毒性可以通过个性化治疗调整来减轻.
免疫治疗的整合在控制毒性方面显示出有前途.

结论:

量身定制的治疗适应和免疫疗法对于管理儿科ALL严重急性毒性至关重要.
这些策略正在成为现代ALL治疗方案的核心.
改善毒性管理将提高儿科ALL幸存者的整体存活率和患者健康.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.